DelveInsight’s “Chronic Pain Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Chronic Pain, historical and forecasted epidemiology as well as the Chronic Pain market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Chronic Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Pain Market Forecast
Some of the key facts of the Chronic Pain Market Report:
-
The Chronic Pain market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
-
In October 2024, ANANDA Scientific Inc., a biopharmaceutical company focused on research, has announced the start of a clinical trial for Nantheia™ ATL5. This investigational drug utilizes cannabidiol (CBD) and ANANDA’s proprietary delivery technology, in combination with delta-9-tetrahydrocannabinol (THC), to assess its potential effectiveness in treating patients with both opioid use disorder (OUD) and chronic pain.
-
In 2023, the United States had the highest number of prevalent chronic pain cases among the 7MM countries.
-
In the EU4 and the UK, the United Kingdom accounted for the highest percentage of chronic pain prevalent cases, approximately 30%.
-
In 2023, around 70% of chronic pain cases in the United States were classified as moderate to severe in terms of severity.
-
Medications approved for treating chronic pain from various causes include EMGALITY (galcanezumab-gnlm), TARLIGE (mirogabalin besylate), AIMOVIG (erenumab-aooe), AJOVY (fremanezumab), VYEPTI (eptinezumab), and PENNSAID Gel.
-
Key Chronic Pain Companies: Seikagaku Corporation/Chiltern International, Pacira BioSciences, Paradigm Biopharmaceuticals, Tonix Pharmaceuticals, and others
-
Key Chronic Pain Therapies: JOYCLU (diclofenac etalhyaluronate sodium), ZILRETTA (triamcinolone acetonide extended-release injectable suspension), ZILOSUL (pentosan polysulfate sodium), TNX-102 SL, and others
-
The Chronic Pain market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Pain pipeline products will significantly revolutionize the Chronic Pain market dynamics.
Chronic Pain Overview
Chronic pain is long-lasting discomfort or pain that persists for 12 weeks or more, even after the initial injury or illness has healed. It can result from various conditions, such as arthritis, nerve damage, or past injuries, and can significantly impact a person’s quality of life by affecting mobility, mood, and daily activities. Chronic pain can be managed through a combination of medications, physical therapy, psychological support, and lifestyle changes.
Get a Free sample for the Chronic Pain Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/chronic-pain-market
Chronic Pain Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Chronic Pain Epidemiology Segmentation:
The Chronic Pain market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Total Prevalence of Chronic Pain
-
Prevalent Cases of Chronic Pain by severity
-
Gender-specific Prevalence of Chronic Pain
-
Diagnosed Cases of Episodic and Chronic Chronic Pain
Download the report to understand which factors are driving Chronic Pain epidemiology trends @ Chronic Pain Epidemiology Forecast
Chronic Pain Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Pain market or expected to get launched during the study period. The analysis covers Chronic Pain market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Chronic Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Chronic Pain Therapies and Key Companies
-
JOYCLU (diclofenac etalhyaluronate sodium): Seikagaku Corporation/Chiltern International
-
ZILRETTA (triamcinolone acetonide extended-release injectable suspension): Pacira BioSciences
-
ZILOSUL (pentosan polysulfate sodium): Paradigm Biopharmaceuticals
-
TNX-102 SL: Tonix Pharmaceuticals
Discover more about therapies set to grab major Chronic Pain market share @ Chronic Pain Treatment Landscape
Scope of the Chronic Pain Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Chronic Pain Companies: Seikagaku Corporation/Chiltern International, Pacira BioSciences, Paradigm Biopharmaceuticals, Tonix Pharmaceuticals, and others
-
Key Chronic Pain Therapies: JOYCLU (diclofenac etalhyaluronate sodium), ZILRETTA (triamcinolone acetonide extended-release injectable suspension), ZILOSUL (pentosan polysulfate sodium), TNX-102 SL, and others
-
Chronic Pain Therapeutic Assessment: Chronic Pain current marketed and Chronic Pain emerging therapies
-
Chronic Pain Market Dynamics: Chronic Pain market drivers and Chronic Pain market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Chronic Pain Unmet Needs, KOL’s views, Analyst’s views, Chronic Pain Market Access and Reimbursement
To know more about Chronic Pain companies working in the treatment market, visit @ Chronic Pain Clinical Trials and Therapeutic Assessment
Table of Contents
1. Chronic Pain Market Report Introduction
2. Executive Summary for Chronic Pain
3. SWOT analysis of Chronic Pain
4. Chronic Pain Patient Share (%) Overview at a Glance
5. Chronic Pain Market Overview at a Glance
6. Chronic Pain Disease Background and Overview
7. Chronic Pain Epidemiology and Patient Population
8. Country-Specific Patient Population of Chronic Pain
9. Chronic Pain Current Treatment and Medical Practices
10. Chronic Pain Unmet Needs
11. Chronic Pain Emerging Therapies
12. Chronic Pain Market Outlook
13. Country-Wise Chronic Pain Market Analysis (2020–2034)
14. Chronic Pain Market Access and Reimbursement of Therapies
15. Chronic Pain Market Drivers
16. Chronic Pain Market Barriers
17. Chronic Pain Appendix
18. Chronic Pain Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/